123 related articles for article (PubMed ID: 3958781)
1. Effect of combined AZQ and radiation on the tolerance of the rat spinal cord.
Ang KK; van der Kogel AJ; van der Schueren E
J Neurooncol; 1986; 3(4):349-52. PubMed ID: 3958781
[TBL] [Abstract][Full Text] [Related]
2. Toxicity of aziridinylbenzoquinone for aerobic and hypoxic cells of a transplanted mouse mammary tumor and interaction of the drug with radiation and adriamycin.
Tannock I
Cancer Res; 1983 May; 43(5):2059-62. PubMed ID: 6831436
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of aziridinylbenzoquinone (NSC 192986) in patients with previously treated acute leukemia.
Van Echo DA; Schulman P; Budman DR; Ferrari A; Wiernik PH
Am J Clin Oncol; 1982 Aug; 5(4):405-10. PubMed ID: 7113963
[TBL] [Abstract][Full Text] [Related]
4. Decreased cytotoxicity of aziridinylbenzoquinone caused by polyamine depletion in 9L rat brain tumor cells in vitro.
Alhonen-Hongisto L; Deen DF; Marton LJ
Cancer Res; 1984 Jan; 44(1):39-42. PubMed ID: 6418379
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
Tan CT; Hancock CH; Mondora A; Hoffman NW
Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid pharmacokinetics of intraventricular and intravenous aziridinylbenzoquinone.
Zimm S; Collins JM; Curt GA; O'Neill D; Poplack DG
Cancer Res; 1984 Apr; 44(4):1698-701. PubMed ID: 6704975
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory small cell carcinoma of the lung.
Fuks JZ; Aisner J; Van Echo DA; Levitt M; Ihde DC; Carney D; Wiernik PH
Am J Clin Oncol; 1983 Apr; 6(2):171-3. PubMed ID: 6299094
[TBL] [Abstract][Full Text] [Related]
8. Aziridinylbenzoquinone (AZQ) treatment of central nervous system leukemia.
Kamen BA; Holcenberg JS; Siegel SE
Cancer Treat Rep; 1982 Dec; 66(12):2105-6. PubMed ID: 6958367
[No Abstract] [Full Text] [Related]
9. Phase II study of an aziridinylbenzoquinone (AZQ) in disseminated malignant melanoma.
Creagan ET; Schutt AJ; Ahmann DL; Green SJ
Cancer Treat Rep; 1982 Dec; 66(12):2089-90. PubMed ID: 7139650
[TBL] [Abstract][Full Text] [Related]
10. The influence of AZQ on the DNA distribution of human cerebral tumours in short-term culture.
Sieben G; Calliauw L; van Oostveldt P; Roels H
Eur J Cancer Clin Oncol; 1985 Feb; 21(2):217-20. PubMed ID: 3987758
[TBL] [Abstract][Full Text] [Related]
11. AZQ therapy in patients with disseminated malignant melanoma.
Yap BS; Bedikian AY; Burgess MA; Bodey GP
Am J Clin Oncol; 1982 Dec; 5(6):623-5. PubMed ID: 7165003
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of aziridinylbenzoquinone (AZQ) in patients with central nervous system malignancies: a Southwest Oncology Group Study.
Taylor SA; McCracken JD; Eyre HJ; O'Bryan RM; Neilan BA
J Neurooncol; 1985; 3(2):131-5. PubMed ID: 2993536
[TBL] [Abstract][Full Text] [Related]
13. Cellular pharmacology in murine and human leukemic cell lines of diaziquone (NSC 182986).
Egorin MJ; Fox BM; Spiegel JF; Gutierrez PL; Friedman RD; Bachur NR
Cancer Res; 1985 Mar; 45(3):992-9. PubMed ID: 3971389
[TBL] [Abstract][Full Text] [Related]
14. The influence of diaziquone free radicals on the in vitro activity of diaziquone.
Nguyen B; Biswal S; Gutierrez PL
Xenobiotica; 1988 May; 18(5):593-602. PubMed ID: 2840783
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation. Preliminary report.
Decker DA; Al Sarraf M; Kresge C; Austin D; Wilner HI
J Neurooncol; 1985; 3(1):19-21. PubMed ID: 2987424
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive phase II evaluation of aziridinylbenzoquinone (AZQ, diaziquone) in recurrent human primary brain tumors.
Eagan RT; Dinapoli RP; Cascino TL; Scheithauer B; O'Neill BP; O'Fallon JR
J Neurooncol; 1987; 5(4):309-14. PubMed ID: 3440875
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of aziridinylbenzoquinone (AZQ) in head and neck cancer.
Forastiere AA; Crain SM; Callahan K; Van Echo D; Mattox D; Thant M; Von Hoff DD; Wiernik PH
Cancer Treat Rep; 1982 Dec; 66(12):2097-8. PubMed ID: 6892491
[No Abstract] [Full Text] [Related]
18. Phase I study of aziridinylbenzoquinone (NSC 182986).
Bedikian AY; Bodey GP; Burgess MA; Freireich EJ
Cancer Clin Trials; 1981; 4(4):459-63. PubMed ID: 7318128
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial toxicity of 2,5-diaziridinyl-3,6-bis-(carboethoxyamino)-1,4-benzoquinone.
Oberc-Greenwood MA; Smith BH; Cooke C; Ellis JR; Kornblith PL; McKeever PE
J Natl Cancer Inst; 1983 Oct; 71(4):725-33. PubMed ID: 6578368
[TBL] [Abstract][Full Text] [Related]
20. Aziridinylbenzoquinone (AZQ) in advanced breast cancer: a Cancer and Leukemia group B phase II trial.
Budman DR; Forastiere A; Perloff M; Perry M; Aisner J; Weinberg V; Wood W
Cancer Treat Rep; 1982 Oct; 66(10):1875-6. PubMed ID: 7127327
[No Abstract] [Full Text] [Related]
[Next] [New Search]
